| abstract |
Oxazolidinone derivatives of formula (1) are described where: R1 is H, Ar-CO-, A-CO-, OH, OA, Ar-O-CO-, AO-CO-, Ar-SO2 or A-SO2; R2 is H, A 'or benzyl; A, A 'and A' 'are each, independently, C1-6 alkyl; Ar is phenyl or naphthyl, each of which is unsubstituted or mono, di or trisubstituted with A, F, Cl, Br, OA '', COOA '', COOH, CF3, OH, NO2, CN, NH2 , NHA, NA2 or -O-CO-A ''; and n is 1 or 2; and its salts and solvates acceptable for physiological use. These compounds block the interaction of integrin receptors and ligands such as fibrinogen in the fibrinogen receptor (glycoprotein IIb / IIIa), and prevent, as a GPIIb / IIIa antagonist, the spread of tumor cells through Metastasis They also inhibit the binding of other adhesive proteins such as, for example, vitronectin, collagen and laminin, to the corresponding receptors on the surface of various cell types. A procedure for preparing the compounds of formula (1), the medicines based on these compounds, the pharmaceutical preparations containing them and the use thereof to prepare a medicament for the treatment of thrombosis, osteoporosis, tumor diseases is also described. , stroke, heart attack, ischemia, inflammations, arteriosclerosis and osteolytic diseases. |